digenous component as per conditions of the Licence. However, there was no indigenous production of Penicillin 'V'. The requisite details regarding excess imports of Penicillin-G during the year 1989-90 are given in the enclosed statement. The details about the shortfall in indigenous lifting have been brought to the notice of the CCL&E for taking action against these companies for violating the conditions of import.

Statement

(IN MMU)

S. No.	Name of company	Quantity of indigenous material which was due to be lifted during 1989-90	Actual imports granted	Total indigenous material lifted	Balance quantity of indigenous material to be lifted
1	M/s. Alembic Chemicals	10·71	25	5·02	5·69
2	M/s. Wellchem Labs.	4·50	10·50	1 241	3·259
3	M/s. Lawande	4·75	11·09	2·793	1·957
4	M/s. Camphem Labs	13·118	30·608	4·943	8·175
5	M/s. S. Canomax	4·50	10 50	0·506	3·994
6	M/s. Jagsonpal	15	35		15
7	M/s. Pharm Chem.	17·41	40·0	..	17·41

Produtcion of bulk drugs from basic stage

214. SHRI H. HANUMANTHAPPA: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that according to Drug Policy 1986 the changes in customs duty are made with a view to boosting production of bulk drugs from basic stages;

(b) if so, whether it is a fact that a number of bulk drugs and intermediates on which customs duty concessions were given are still being imported;

(c) if so, what are the names of bulk drugs and drug intermediates on which concessions were given since last more than three years;

(d) whether it is also a fact that these drugs are still being imported; and

(e) if so, since when each drug is being imported or produced from imported intermediate and what steps have been taken for production from basic stage in each case?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) The purpose of duty rationalisation as envisaged in measures announced in 1986 was to progressively minimise the duties, excise and customs, on drugs in such a way that cost efficient production is encouraged.

(b) Yes, Sir.

(c) The number of bulk drugs and intermediates on which duty concessions have been given during the last three years is quite large and time and efforts involved in cutting

out their details from various notifications would not be commensurate with the results likely to be achieved.

(d) and (e) To the extent availability in the country is not adequate, imports are required to be arranged. Manufacturers are required to produce the drugs based on the Conditions/Phased Manufacturing Programme stipulated in the industrial approvals granted to them from time to time which aims at basic stage production ultimately.

Allocation of Penicillin G/V

215. SHRI ASHOK NATH VERMA:

DR. RATNAKAR PANDEY:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what is the estimated demand of Penicillin G/V during 1990-91 and 1991-92;

(b) what was the production of Penicillin G/V during the last three years, year-wise and unitwise;

(c) what is the current price per unit and what was the price in 1988-89 and 1989-90;

(d) whether it is a fact that allocation of indigenous production is done by his Ministry; and

(e) on what basis allocation is made and what are the names of companies to whom indigenous material was allocated during 1989-90 and upto 31st December, 1990 and at what price and what quantity was allocated to each?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) The demand of Penicillin during the year 1990-91 and 1991-92 is estimated as 1877 MMU and 2109 MMU respectively.

(b) The production of Penicillin-G during the year 1987-88, 1988-89 and 1989-90 in respect of public sector units is given below:—

Unit	Production (In MMU)		
	1987-88	1988-89	1989-90
IDPL	227·80	284·40	353·06
HAL	264·05	323·68	385·69

(c) The notified Price of indigenous Penicillin-G First Crystals was Rs. 650/BOU w.e.f. 22-1-87 which has been revised to Rs. 695/BOU w.e.f. 1-8-90.

(d) Yes, Sir.

(e) Indigenous Penicillin-G was allocated at the notified price in accordance with the Penicillin-G Policy for 1989-90 and 1990-91 (till December, 1990) to various companies as per statement.

Statement

S. No.	Name of the company
1.	M|s. Cadila Labs
2.	M|s. Duphar Interforan
3.	M|s. Lupin Labs
4.	M|s. Aurbindo Pharma
5.	M|s. Kopran Chemicals
6.	M|s. Armour Chemicals
7.	M|s. Agipi
8.	Ms. SOL
9.	M|s. Fermenta Pharma